Roche secures regulatory approval for Ocrevus in Australia

17 July 2017
2019_biotech_test_vial_discovery_big

Australia’s medicines regulator, the Therapeutic Goods Administration, has approved Swiss pharma firm Roche’s (ROG: SIX) application to market Ocrevus (ocrelizumab) as a treatment for multiple sclerosis.

It’s the second regulatory approval for Roche in two indications: relapsing forms of multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS).

Approval in these indications in the USA, given in March, sent the company’s share price climbing as investors considered a potential $3 billion revenue boost for the company.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology